Windtree Therapeutics (NASDAQ:WINT – Get Free Report) is expected to release its Q4 2025 results after the market closes on Wednesday, April 8th. Analysts expect Windtree Therapeutics to post earnings of $18.00 per share and revenue of $3.80 million for the quarter. Parties may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Wednesday, April 15, 2026 at 12:30 PM ET.
Windtree Therapeutics Trading Up 16.1%
WINT opened at $0.01 on Wednesday. The business’s 50 day moving average is $0.01 and its 200-day moving average is $0.05. The stock has a market cap of $485,870.40, a PE ratio of 0.00 and a beta of 0.69. Windtree Therapeutics has a twelve month low of $0.01 and a twelve month high of $1.86.
Windtree Therapeutics Company Profile
Windtree Therapeutics, Inc is a clinical-stage biotechnology company developing innovative therapies for acute cardiovascular and pulmonary conditions. The company leverages its proprietary KL4 surfactant technology to address diseases marked by surfactant deficiency or dysfunction, with a primary focus on acute respiratory distress syndrome (ARDS) in adults and respiratory distress syndrome (RDS) in premature infants.
The company’s lead platform comprises synthetic peptide‐based surfactants designed to restore lung function by reducing surface tension in the alveoli.
See Also
Receive News & Ratings for Windtree Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Windtree Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
